Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...
Tag: Nivolumab
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors
1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...
Nivolumab+AVD Improves Survival in Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Perioperative Nivolumab in Resectable Lung Cancer
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR ...
#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
#VisualAbstract: Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...